Receptor-ligand supplementation via a self-cleaving 2A peptide–based gene therapy promotes CNS axonal transport with functional recovery-Reference-Cited by-同舟云学术

Receptor-ligand supplementation via a self-cleaving 2A peptide–based gene therapy promotes CNS axonal transport with functional recovery

Published:2021-04-02 Issue:14 Volume:7 Page:
ISSN:2375-2548
Container-title:Science Advances
language:en
Short-container-title:Sci. Adv.

Author:

Khatib Tasneem Z.¹²³^ORCID,Osborne Andrew¹⁴⁵,Yang Sujeong¹,Ali Zara¹⁶^ORCID,Jia Wanyi¹,Manyakin Ilya⁷,Hall Katie¹^ORCID,Watt Robert¹,Widdowson Peter S.⁴⁵,Martin Keith R.¹²⁴⁸⁹

Affiliation:

1. Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.

2. Eye Department, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.

3. Medical Sciences Division, University of Oxford, Oxford, UK.

4. Quethera Ltd., Cambridge, UK.

5. Ikarovec Ltd., Norwich Innovation Centre, Norwich, UK.

6. School of Clinical Medicine, University of Cambridge, Cambridge, UK.

7. Department of Physics, University of Cambridge, Cambridge, UK.

8. Cambridge NIHR Biomedical Research Centre, Cambridge, UK.

9. Wellcome Trust—MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK.

Abstract

From vision impairment to memory loss, neurotrophin and receptor supplementation using gene therapy promotes functional recovery.

Funder

Fight for Sight

Wellcome

Alzheimer’s Research UK

Addenbrooke’s Charitable Trust, Cambridge University Hospitals

Gates Cambridge Trust

Cambridge Eye Trust

Jukes Glaucoma Research Fund

Quethera Ltd

MRC to the Wellcome Trust – Medical Research Council Cambridge Stem Cell Institute

Medical Research Council Canada

Mauritius Research Council

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference65 articles.

1. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65 -mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial

2. Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy

3. Safety of rAAV2/2- ND4 Gene Therapy for Leber Hereditary Optic Neuropathy

4. Induction of corticospinal regeneration by lentiviral trkB-induced Erk activation

5. Neocortical neurons lacking the protein-tyrosine kinase B receptor display abnormal differentiation and process elongation in vitro and in vivo

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Review: Neuroprotective Nanocarriers in Glaucoma;Pharmaceuticals;2024-09-10

2. Covalently linked adenovirus-AAV complexes as a novel platform technology for gene therapy;2024-08-21

3. Monogenic gene therapy for glaucoma and optic nerve injury;Neural Regeneration Research;2024-05-17

4. Addressing neurodegeneration in glaucoma: Mechanisms, challenges, and treatments;Progress in Retinal and Eye Research;2024-05

5. Recombinant expression and subcellular targeting of the particulate methane monooxygenase (pMMO) protein components in plants;Scientific Reports;2023-09-15